

Date and Time: *Wednesday 18 February 2015, 10am-4.00 pm*

Minutes: Confirmed

Cirrhosis Guideline Development Group Meeting 6

Place: *Boardroom, NCGC, 180 Great Portland Street, London*

Present:	Phil Harrison (Chair)	Consultant Hepatologist
	Marsha Morgan	Principle Research Fellow/Honorary Consultant Physician
	Susan McRae	Patient/Carer Member
	Andrew Fowell	Consultant Gastroenterologist and Hepatologist
	Lynda Greenslade	Clinical Nurse Specialist in Hepatology
	Valerie Ross	Lead Pharmacist, Hepatology
	Mark Hudson	Consultant Hepatologist
	Iain Brew	General Practitioner
	Gerri Mortimore	Lead CNS Liver
	David Fitzmaurice (co-optee)	General Practitioner
	Emily Davies	Senior Research Fellow, NCGC
	Gill Ritchie	Associate Director, NCGC
	Ben Pordes	Project Manager, NCGC
	Brian Hogan	Specialist Registrar in Hepatology and Intensive Medicine
	Lefteris Floros	Health Economist, NCGC
	Martin J Harker	Senior Health Economist, NCGC

In attendance:

NICE Staff: Caroline Keir		
------------------------------	--	--

Apologies:

Andrew Langford, Patient/Carer Member

Katie Broomfield, Document Editor/Process Assistant, NCGC

Stacey Lockyer, Research Fellow, NCGC

Notes

1. The Chair welcomed the group to the sixth meeting of this GDG. Apologies were received from AL, SL and KB. The Chair reviewed and requested updates to the declarations of interest register. The Chair declared that in relation to the **previous** declarations recorded in the DOI register, for this meeting, no action was required.

New declarations of interest received for this GDG meeting include:

GDG Declarations of Interest
N.B. The Chair and GDG members were recruited to this guideline using NICE DOI policy published Oct 2008.

Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chairs action
IB	Delivered a lecture on hepatitis C treatment in prisons for Gilead: honorarium payable	Personal financial non-specific	Declare and participate
	Conference and travel costs covered by Janssen for a hepatitis C meeting	Personal financial non-specific	No action required
VR	I have been offered and accepted sponsorship by Abbvie to attend the EASL conference in April 2015 in Vienna.	Personal financial non-specific	Declare and participate

2. The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.
3. ED updated the GDG on the search for additional studies for the Diagnostic tests review.
4. MJH presented to the GDG on inputs for the health economic model.
5. ED presented to the GDG on interpreting prognostic risk tool reviews and prognostic risk factor reviews.
6. ED presented the clinical evidence review on risk tools and risk factors for cirrhosis. LF presented the health economic evidence. The GDG discussed the evidence.
7. ED presented the clinical evidence review on volume replacers in hepatorenal syndrome. LF presented the health economic evidence. The GDG discussed the evidence.
8. ED asked the GDG about the population to be included in the detection of hepatocellular carcinoma protocol.
9. There was no other business.

Date, time and venue of the next meeting

Thursday 26 March 2015; Linacre room at the RCP; 10am-4pm